Carlsbad, CA, United States
Carlsbad, CA, United States

Time filter

Source Type

MENA Cosmetic Skin Care Market: Overview In terms of revenue, the Middle East and North Africa (MENA) cosmetic skin care market is expected to register a CAGR of 8.0% during the forecast period, 2016–2024. The primary objective of the report is to offer insights on the market dynamics that can influence growth of the Middle East and North Africa (MENA) cosmetic skin care market over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the Middle East and North Africa (MENA) cosmetic skin care market are presented in the report. Download the full report: https://www.reportbuyer.com/product/4885787/ The Middle East and North Africa (MENA) cosmetic skin care market is expected to witness significant growth rate in terms of value owing to rise in cosmetic and aesthetic procedures and increase in demand for premium. Moreover, growing aging population, rise in disposable income, heavy research and development in cosmetic skin care products, and change in lifestyle are creating high potential growth opportunities for players operating in the Middle East and North Africa (MENA) cosmetic skin care market. Revenue from the cosmetic skin care market in Middle East and North Africa (MENA) is expected to expand at the relatively higher CAGR due to increasing outbound medical tourism and rising demand for skin care products in the region. To understand and assess opportunities in this market, the report offers market forecast on the basis of product type and distribution channels in Middle East and North Africa (MENA). The report provides analysis of the Middle East and North Africa (MENA) cosmetic skin care market in terms of market value (US$ Mn) and volume (In number of procedures). MENA Cosmetic Skin Care Market: Key Segments The Middle East and North Africa (MENA) cosmetic skin care market is segmented on the basis of product type: Anti-Aging Skin Whitening Sensitive Skin Anti-Acne Dry Care Bath & Shower Intimate Hygiene Others The Middle East and North Africa (MENA) cosmetic skin care market is segmented on the basis of various distribution channels: Super Markets and Hyper Markets Departmental Stores and Convenience Stores Spas Pharmacies Others The report begins with the market definition, followed by overview of the different product types and various distribution channels. The market dynamics section includes TMR's analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the Middle East and North Africa (MENA) cosmetic skin care market. MENA Cosmetic Skin Care Market: Scope of the Report Next, the report analyses the market on the basis of regions and presents forecast in terms of value for the next 10 years. In addition, we have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the Middle East and North Africa (MENA) cosmetic skin care market. Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked, while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for products offered through cosmetic skin care in Middle East and North Africa (MENA). To understand key segments in terms of their growth and performance in the Middle East and North Africa (MENA) cosmetic skin care market, Transparency market research has developed a market attractiveness index. The resulting index would help providers identify existing market opportunities. In the final section of the report, a 'competitive landscape' has been included to provide a dashboard view of key companies operating in the Middle East and North Africa (MENA) cosmetic skin care market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the Middle East and North Africa (MENA) cosmetic skin care market and the potential players. However, this section also includes market strategies and SWOT analysis of the main players operational in the Middle East and North Africa (MENA) cosmetic skin care market. Detailed profiles of players operating in Middle East and North Africa (MENA) cosmetic skin care market are also included in the scope of the report to evaluate their long- and short-term strategies. Companies Mentioned in the Report Key players included in this report are Shiseido Company, Limited, The Estée Lauder Companies Inc., Beiersdorf AG, The Body Shop International plc., THALGO COSMETIC GmbH, Natura Bissé International, S.A., The Aromatherapy Company, L'Oreal Group, ESPA International Ltd., Éminence Organic Skin Care, Pevonia Global, Shiffa Dubai Skin Care Cosmetics LLC, Ascendis.co.za., Unilever, Guinot S.A., Laboratories IPRAD, SkinMedica Inc., and Obagi Medical Products, Inc., among others. Middle East and North Africa (MENA) cosmetic skin care market has been segmented as follows: Middle East and North Africa (MENA) Cosmetic Skin Care Market, By Product Type Anti-Aging Skin Whitening Sensitive Skin Anti-Acne Dry Care Bath & Shower Intimate Hygiene Others Middle East and North Africa (MENA) Cosmetic Skin Care Market, By Distribution Channel Super Markets and Hyper Markets Departmental Stores and Convenience Stores Spas Pharmacies Download the full report: https://www.reportbuyer.com/product/4885787/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cosmetic-skin-care-market---middle-east-and-north-africa-industry-analysis-size-share-growth-trends-and-forecast-2016---2024-300453659.html


News Article | May 16, 2017
Site: www.prweb.com

Dr. Jeff Alexander is proud to announce that Skin Care Institute Medical and Wellness Spa is the leading provider of CoolSculpting in Oklahoma and Arkansas, as determined by Allergan, the new owner of CoolSculpting. FDA-cleared CoolSculpting is the world’s number one non-invasive fat-reduction procedure, providing slimmer and trimmer contours to more than 4 million people worldwide. Despite healthy lifestyle habits, many people have lingering “problem” spots of fat on their bodies that are resistant to diet and exercise. CoolSculpting is ideal for reducing these stubborn pockets of fat on almost any area of the body, from the chin to underneath the buttocks, without any downtime or invasive surgery. That’s why Dr. Alexander and the Skin Care Institute team provide this service—to help patients achieve their ideal body contours with the ease and efficiency that only CoolSculpting can offer. Using gentle cooling technology, CoolSculpting freezes away targeted fat cells, which are then naturally expelled from the body in the months following treatment. Once fat cells are disrupted and leave the body, they can never return, making CoolSculpting a long-lasting fat reduction treatment with zero downtime. For added comfort and convenience, Skin Care Institute proudly offers DualSculpting, allowing two areas of the body to be treated at the same time, as well as the most advanced technology that allows shorter treatment times. For CoolSculpting treatments and additional information, Skin Care Institute Medical and Wellness Spa can be reached by calling 918.948.9639. Since opening in 1999, Medical Director Dr. Jeff Alexander and his wife, Judy Alexander, have shared the mission to provide both men and women with the best in skin care and wellness. Skin Care Institute’s services have always been based on a balanced blend of science and aesthetics. Dermatologist Jeff Alexander, MD constantly seeks the newest, safest and most effective technology for skin rejuvenation and anti-aging. A balanced blend of science and aesthetics is the foundation for the services provided by Skin Care Institute Medical and Wellness Spa. Skin Care Institute’s licensed professionals provide the finest treatments and products in the relaxing and soothing atmosphere of a modern spa setting. With this combination, Skin Care Institute has become Oklahoma’s premier medical spa, offering a leading selection of treatments including laser skin rejuvenation, skin tightening, chemical peels, massage therapy, skin care products and more. Skin Care Institute Medical and Wellness Spa, is located in the Kelly Medical Building at 6565 South Yale Avenue, Suite 110 in Tulsa, Oklahoma. About Dr. Jeff Alexander, Medical Director of Skin Care Institute Jeff Alexander, MD, is the owner and medical director of Skin Care Institute Medical and Wellness Spa in Tulsa, OK. He is certified by the American Board of Dermatology and has over 30 years of experience in skin care. He is a graduate of the University of Nebraska Medical School and the University of Oklahoma Dermatology Program. He has served as president of the Oklahoma Dermatological Society and the Tulsa Dermatological Society. He is currently the chairman of the Department of Dermatology at St. Francis Hospital in Tulsa. He has served on the speaker’s bureau for GlaxoSmithKline, SkinCeuticals, Novartis Pharmaceuticals and SkinMedica. He has also served as assistant clinical professor and dermatology instructor for medical students and residents at the University of Oklahoma. In 1999, Dr. Alexander opened Skin Care Institute, the first medical spa in Oklahoma. By combining cutting-edge laser technology with aesthetic and medical procedures, he paved the way for others in the industry. In 2011, Dr. Alexander became the first in Oklahoma to offer CoolSculpting® by ZELTIQ®.


News Article | April 17, 2017
Site: www.prweb.com

Winter Park Laser & Anti-Aging Center presents a revolutionary new skin care product that reduces pigmentation to enhance surgical and nonsurgical procedures—Lytera 2.0 by SkinMedica. Lytera 2.0 is the primary supportive cosmeceutical product to help patients eradicate dark spots from the face, neck and décolletage in as little as 4 weeks. Skin pigmentation is one of the most common skin conditions patients suffer from in the cosmetic and plastics industry with scant solutions, until now. “Lytera 2.0 is the most promising cosmeceutical product available for patients looking to counter high levels of pigmentation in the skin. Our patients have seen real results in combination with laser skin resurfacing, IPL, and as a stand-alone product in just a few weeks.”—Aneta K. Filardo, Owner MBA and C.M.E As skin care products appear on the market every day, Lytera 2.0 is a definitive correcting serum that goes deeper than any other to break melanin-dense areas of the skin to soften and reduce dark areas. Patients in Orlando are recommended to use this product as a supplementary support for skin resurfacing treatments such as laser resurfacing, chemical peels, and microdermabrasion. Lytera reveals a brighter and more even skin tone in as little as two weeks, with optimal results appearing at 12 weeks. This skin care product is the first of its kind to target pigmentation in all Fitzpatrick skin tones and types. Our patients are offered a detailed assessment of their skin so that we can create a custom treatment plan for pigmentation with Lytera 2.0. Patients love this product because they see results firsthand and can apply it at home, since it fares well with all other skin care regimens. While most skin care products are full of parabens and unnecessary fragrances which cause buildup in pores, Lytera 2.0 is made with only necessary ingredients, making it the lightest product in its class. All active ingredients include: Tranexamic Acid—targets pigmentation Marine Extract—improves healthy skin base Phenylethyl Resorcinol—balances high levels of melanin Niacinamide, Tetrapeptide-30 and Phytic Acid—even skin tone and smooth texture Winter Park Laser & Anti-Aging Center, one of the top 50 Allergan providers, is a high-end medical spa treating patients for the last 13 years with injectables, body contouring, laser skin resurfacing, hair and tattoo removal, and anti-aging treatments. As a leader in patient care, Winter Park educates clients on the proper treatments and skin care methods to help them achieve their aesthetic goals, invested in the journey to healthy and beautiful skin. Learn more about Winter Park Laser & Anti-Aging Center by visiting our website at http://www.WinterParkLaser.com.


Patent
Arch Personal Care Products L.P. and SkinMedica | Date: 2011-11-11

Compositions comprising metabolized conditioned growth medium and/or metabolized cell extract and methods of use are described. The metabolized conditioned growth medium and metabolized cell extract compositions may be formulated with an acceptable carrier into injectable or topical formulations, for example, as a cream, lotion or gel, and may be used in cosmeceutical or pharmaceutical applications. The metabolized conditioned growth medium and metabolized cell extract may also be further processed to concentrate or reduce one or more factors or components contained within the metabolized conditioned growth medium or metabolized cell extract. The growth medium may be conditioned by any eukaryotic cell. The metabolized conditioned growth medium and metabolized cell extract may be used to prevent or treat a condition, for example, a skin condition.


News Article | February 15, 2017
Site: www.prweb.com

Sara Shikhman, Practice Manager of Juvly Aesthetics in Ohio and New York City was selected as one of few aesthetic professionals in the country to sit on the 2017 National Advisory Board for Allergan’s Brilliant Distinctions consumer loyalty program. As Practice Manager of Juvly Aesthetics, in just 2 years Sara helped propel the clinic from a small start-up to number 78 in the country based on sales volume of Allergan cosmetic products, while earning 5 star ratings from Juvly clients. Juvly’s motto is fair prices and fantastic results, and all prices are posted online at http://www.juvly.com/pricing. "The invitation by Allergan to serve on this Advisory Board is not only an honor but also a great example of Allergan's commitment to innovation and research," she said. "I am hopeful that our Board's contributions will enrich the Brilliant Distinctions Program so that Botox® clients all over the United States will realize even more savings. The Advisory Board is meeting in February 2017 in Dana Point, CA. About Juvly Aesthetics Founded by Dr. Justin Harper in 2014, Juvly Aesthetics has grown to one of the largest and most highly acclaimed aesthetic practices in the country. Juvly has offices in Columbus, OH, New York, NY, Cincinnati, OH and Polaris, OH. The clinic specializes in non-surgical aesthetic procedures including Allergan’s portfolio of injectable products. In addition, Juvly offers anti-aging laser procedures, non-surgical fat reduction with Coolsculpting and Cellfina cellulite reduction treatments. About Allergan Allergan is the global multi-specialty health care corporation that produces cosmetic products such as Botox®, Juvederm®, Juvederm Voluma®, Kybella®, Juvederm Volbella®, Latisse® and SkinMedica®. Brilliant Distinctions® is Allergan's customer loyalty program.


Makino E.T.,SkinMedica
Journal of drugs in dermatology : JDD | Year: 2013

There are numerous common skin disorders involving hyperpigmentation, including solar lentigines, postinflammatory hyperpigmentation, melasma, freckles, and dyschromia from photoaging. While these conditions are of an aesthetic nature, there is great interest in newer, safer, and more effective treatment modalities. Topical hydroquinone (HQ) has been the gold standard of skin lighteners for many years. However, regulatory authorities around the world are now questioning its safety. A randomized, double-blind, half-face study was conducted in females with moderate to severe facial hyperpigmentation to assess the efficacy and tolerability of 3 new skin brightener formulations containing SMA-432, a prostaglandin E2 inhibitor, compared with 4% HQ. Each subject was assigned 2 of the 4 test materials and was instructed to apply the product on the assigned side of the face twice daily for 12 weeks. Evaluation visits were conducted at baseline and at 4, 8, and 12 weeks. At each visit, subjects were evaluated by a blinded investigator for clinical efficacy and tolerability using grading scales. Standardized digital photography and Chroma Meter assessments were also taken. Self-assessment questionnaires were completed at weeks 4, 8, and 12. Sixty-eight Caucasian subjects (136 half faces) completed the study. All test materials significantly reduced Overall Hyperpigmentation and improved the Investigator's Global Hyperpigmentation Improvement rating at weeks 4, 8, and 12 compared with baseline. SMA-432 exhibited a dose-dependent improvement in hyperpigmentation. There were no major tolerability issues with any of the test materials. Self-assessments were generally favorable for all test materials. At the completion of the trial, subjects rated one of the tested multimodality brightener compositions as the most favorable product and 4% HQ as the least favorable. This study demonstrated that the new non-HQ-containing skin brightener formulations were as effective and equally well tolerated as the gold standard, 4% HQ, in females with facial hyperpigmentation.


Patent
SkinMedica | Date: 2012-06-25

A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. A representative composition comprises 4-ethoxybenzaldehyde and one or more additional active agents as well as a pharmaceutically acceptable carrier or excipient. Carriers and excipients may be formulated for topical administration. Compositions may also be formulated for transdermal administration. The compositions may be used for the prevention and treatment of pigmentation disorders, by way of non-limited example, post-inflammatory hyperpigmentation and others. The compositions may be used for lightening skin.


Patent
SkinMedica | Date: 2012-01-06

A method for the modification of melanin distribution, and the composition thereof to modify melanin distribution are disclosed. A method for the reduction of melanin distribution, and the composition thereof to reduce melanin distribution are disclosed. A representative composition comprises 4-ethoxybenzaldehyde and one or more additional active agents as well as a pharmaceutically acceptable carrier or excipient. Carriers and excipients may be formulated for topical administration. Compositions may also be formulated for transdermal administration. The compositions may be used for the prevention and treatment of pigmentation disorders, by way of non-limited example, post-inflammatory hyperpigmentation and others. The compositions may be used for lightening skin.


Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.


Patent
SkinMedica | Date: 2011-09-23

The present invention provides a skin peel composition including a plurality of substances, such as lactic acid, salicylic acid, and resorcinol and, additionally a post-inflammatory hyper pigmentation reducing substance such as a retinol (vitamin A) or retinol derivative. Skin is first prepared using an alcohol preparation followed by a combinations of acids and, lastly, a retinol or retinol derivatives. Other agents such as ascorbic acid (vitamin C) and vitamin E can be added as needed. Application of the skin peel composition may be either topically in the form of a cream or gel, and may further be injected subcutaneously into the skin to achieve deeper penetration of the composition within the skin layers of the area to be treated.

Loading SkinMedica collaborators
Loading SkinMedica collaborators